This study tests a gene therapy called AGTC-501 in males aged 12 to 50 with X-linked retinitis pigmentosa, a genetic eye disease that causes vision loss. The treatment aims to improve or preserve vision by replacing a faulty gene. Participants receive one of two doses or no treat…
Phase: PHASE2, PHASE3 • Sponsor: Beacon Therapeutics • Aim: Disease control
Last updated May 22, 2026 13:51 UTC